相关实验视频

Updated: May 14, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

金属离子协调茶叶多纳米涂层用于增强的益生菌疗法在炎症性肠病

Lu Gao¹, Yunjian Liu¹, Ling Ye¹

¹School of Food Science and Engineering, South China University of Technology, Guangzhou, 510640, China.

|April 11, 2025

概括

使用替代茶叶多的新金属网络 (MPN) 提高了益生菌的存活率和保留率,用于炎症性肠病 (IBD) 治疗. 涂有表甲素的益生菌 (EGC@L) 在缓解IBD症状和恢复肠道微生物群平衡方面表现出卓越的有效性.

科学领域:

生物材料科学生物材料科学
胃肠病学胃肠病学
微生物学微生物学

背景情况:

金属网络 (MPNs) 在炎症性肠病 (IBD) 中显示出益生菌传递的前景.
现有的MPN系统主要使用酸 (TA),限制了其他多的勘探,并面临稳定性挑战.
替代茶叶多提供了改进MPN配方的潜力.

研究的目的:

制造和评估MPN涂层的Lactobacillus rhamnosus LGG (MPN@L) 使用酸 (GA),表甲基素 (EGC) 和表甲基素酸 (EGCG) 作为酸 (TA) 的替代品.
为了比较这些新型MPN@L配方与基于TA的MPN@L在缓解IBD方面的疗效.
评估MPN@L在IBD模型上的粘附,保留和治疗效果.

主要方法:

使用铁离子和三种替代茶多 (GA,EGC,EGCG) 或酸 (TA) 制造MPN涂层的Lactobacillus rhamnosus LGG.
在ex vivo和in vivo模型中对益生菌粘附和保留的评估.
在小鼠性结肠炎模型中评估治疗效果,包括骨髓氧化酶水平,细胞因子概况和肠道微生物群分析.

主要成果:

与未涂层益生菌相比,所有MPN@L复合物都表现出增强的粘附性和保留性.
在胃肠道消化过程中,EGC涂层益生菌 (EGC@L) 显示出最高的存活率和最佳的肠道保留率.
所有的MPN@L配方都有效地缓解了性结肠炎,而EGC@L显示了有益的肠道细菌的显著改善,并减少了促炎性疾病.

结论:

使用替代茶叶多的金属网络,特别是EGC,为益生菌微封装提供了稳定和生物相容的平台.
在临床前模型中,EGC@L在增强益生菌输送和缓解IBD症状方面表现出卓越的表现.
这种方法扩大了益生菌微囊的潜力,用于治疗像IBD这样的胃肠道疾病.

关键词:

我们的肠道微生物群.炎症性肠病是一种炎症性肠病.金属 - 网络 - 金属 - 网络提供益生菌的传递.一个单细胞封装封装.

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...